April 20, 2018 Conference


How do we improve glaucoma medication adherence?

Dr. Manishi Desai, Boston Medical Center and Boston University School of Medicine (Presenter)

Objective:  The objective of this presentation is to demonstrate to the audience the methods to improve glaucoma medication adherence?

Abstract:  Glaucoma is a degenerative and progressive optic neuropathy that results in irreversible vision loss.  Currently, the mainstay of treatment is medication with laser treatment and surgery available when medication treatment is not sufficient or viable option. Unfortunately studies have shown that adherence to glaucoma medication can be highly variable—ranging from as low as 30% to as high as 75%.  Poor adherence can lead to glaucoma progression and poor outcomes.  Recent estimates reveal that glaucoma affects approximately 5% of the population over 65 years of age and 10% of the population over 75 years of age.  The elderly population is expected to double in the coming decades and along with the aging population so will the number of people with glaucoma.  The problem of non-adherence is only going to be compounded by the higher prevalence of glaucoma in the coming years and will place an ever increasing burden on ophthalmic care not only in terms of cost but also access.  Hence, the problem continues to need solutions and challenges physicians daily. There are a number of steps that physicians can consider to improve compliance with medication including better communication, family support, education, technology, patient support groups, and cost cutting measures.  One method or a combination of methods may ultimately help a particular patient.  This talk will review methods that physicians can consider and use to engage their patients to help individuals improve medication compliance.

World Health Organization (WHO) [Dec 22, 2013];Prevention of Blindness and Visual Impairment. [WHO web site]. Causes of blindness and visual impairment.
Klein R, Klein BE. The prevalence of age-related eye diseases and visual impairment in aging: current estimates. Invest Ophthalmol Vis Sci. 2013;54(14):ORSF5–ORSF13.
US Census Bureau [February 15, 2015];National population projections.
The Advanced Glaucoma Intervention Study (AGIS) 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130(4):429–440.
Leske MC, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48–56.
Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol. 2006 Apr; 17(2):190-5.
Boland MV, Chang DS, Frazier T, Plyler R, Jefferys JL, Friedman DS. Automated telecommunication-based reminders and adherence with once-daily glaucoma medication dosing: the automated dosing reminder study. JAMA Ophthalmol. 2014 Jul; 132(7):845-50.
Waterman H, Evans JR, Gray TA, Henson D, Harper R. Interventions for improving adherence to ocular hypotensive therapy.Cochrane Database Syst Rev. 2013 Apr 30; (4):CD006132. Epub 2013 Apr 30.

Financial Disclosure: None.